A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

China

Fujian Cancer Hospital, Fuzhou, Fujian

Foshan First People's Hospital, Foshan, Guangdong

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Jiangmen Central Hospital, Jiangmen, Guangdong

The Second People's Hospital of Shenzhen, Shenzhen, Guangdong

Guangxi Medical University Cancer Hospital, Nanning, Guangxi

The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou

Harbin Medical University cancer hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Hunan Provincial Tumor Hospital, Changsha, Hunan

Jiangsu Provincial People's Hospital, Nanjing, Jiangsu

First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Jilin Cancer Hospital, Changchun, Jilin

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi

Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong

Sichuan Provincial People's Hospital, Chengdu, Sichuan

Sichuan Cancer Hospital, Chengdu, Sichuan

Leshan People's Hospital, Leshan, Sichuan

Xinjiang Uygur Autonomous Region Cancer Hospital, Ürümqi, Xinjiang

The 1th School of Medicine,School of Information and Engineering.The 1th Affiliated Hospital of WMU, Wenzhou, Zhejiang

Beijing Cancer Hospital, Beijing

Fudan University Shanghai Cancer Center, Shanghai

Tianjin Medical University Cancer Institute&Hpspital, Tianjin